Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.

Saved in:
Bibliographic Details
Title: Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.
Authors: Mansour AG; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Huang Y; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Pemberton JP; Department of Internal Medicine, Virginia Commonwealth University, Health System, Richmond, VA, USA., Alsouqi A; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Kittai AS; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Byrd JC; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Grever MR; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Miller C; Department of Pathology, The Ohio State University, Columbus, OH, USA., Lozanski G; Department of Pathology, The Ohio State University, Columbus, OH, USA., Wiczer T; Department of Pharmacy, The Ohio State University Arthur G James Cancer Hospital, Columbus, OH, USA., Lundberg J; Department of Pharmacy, The Ohio State University Arthur G James Cancer Hospital, Columbus, OH, USA., Rosen L; Department of Pharmacy, The Ohio State University Arthur G James Cancer Hospital, Columbus, OH, USA., Crawford C; Department of Pharmacy, The Ohio State University Arthur G James Cancer Hospital, Columbus, OH, USA., Everhart T; Department of Pharmacy, The Ohio State University Arthur G James Cancer Hospital, Columbus, OH, USA., Moran M; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Lucas M; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Hinton S; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Grantier C; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Hoffman C; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Reid M; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Rogers KA; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Bhat SA; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Woyach JA; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA. jennifer.woyach@osumc.edu.
Source: Leukemia [Leukemia] 2026 Jun 25. Date of Electronic Publication: 2026 Jun 25.
Publication Type: Letter
Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5551
DOI:10.1038/s41375-026-03005-1